M
Marcus A. Mall
Researcher at Humboldt University of Berlin
Publications - 352
Citations - 17457
Marcus A. Mall is an academic researcher from Humboldt University of Berlin. The author has contributed to research in topics: Cystic fibrosis & Cystic fibrosis transmembrane conductance regulator. The author has an hindex of 58, co-authored 300 publications receiving 12703 citations. Previous affiliations of Marcus A. Mall include University of Queensland & University of North Carolina at Chapel Hill.
Papers
More filters
Journal ArticleDOI
SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19.
Julian Braun,Lucie Loyal,Marco Frentsch,Daniel Wendisch,Philipp Georg,Florian Kurth,Florian Kurth,Stefan Hippenstiel,Manuela Dingeldey,Beate Kruse,Florent Fauchere,Emre Baysal,Maike Mangold,Larissa Henze,Roland Lauster,Roland Lauster,Marcus A. Mall,Marcus A. Mall,Kirsten Beyer,Jobst Röhmel,Sebastian Voigt,Jürgen Schmitz,Stefan Miltenyi,Ilja Demuth,Marcel A. Müller,Andreas C. Hocke,Martin Witzenrath,Norbert Suttorp,Florian Kern,Ulf Reimer,Holger Wenschuh,Christian Drosten,Victor M. Corman,Claudia Giesecke-Thiel,Leif E. Sander,Andreas Thiel +35 more
TL;DR: CD4 + T cells that are reactive against the spike glycoprotein of SARS-CoV-2 in the peripheral blood of patients with COVID-19 and healthy donors are found, indicating that spike-protein cross-reactive T cells are present and probably generated during previous encounters with endemic coronaviruses.
Journal ArticleDOI
Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele
Peter G. Middleton,Marcus A. Mall,Pavel Dřevínek,Larry C. Lands,Edward F. McKone,Deepika Polineni,Bonnie W. Ramsey,Jennifer L. Taylor-Cousar,Elizabeth Tullis,François Vermeulen,Gautham Marigowda,Charlotte M. McKee,Samuel M. Moskowitz,Nitin Nair,Jessica H. Savage,Christopher Simard,S. Tian,David Waltz,Fengjuan Xuan,Steven M. Rowe,Raksha Jain +20 more
TL;DR: Elexacaftor-tezacaft or-ivacaft or was efficacious in patients with cystic fibrosis with Phe508del-minimal function genotypes, in whom previous CFTR modulator regimens were ineffective.
Journal ArticleDOI
Increased airway epithelial Na+ absorption produces cystic fibrosis-like lung disease in mice.
TL;DR: It is concluded that increasing airway Na+ absorption initiates cystic fibrosis-like lung disease and produces a model for the study of the pathogenesis and therapy of this disease.
Journal ArticleDOI
Electrolyte Transport in the Mammalian Colon: Mechanisms and Implications for Disease
Karl Kunzelmann,Marcus A. Mall +1 more
TL;DR: Knowledge of the mechanisms of electrolyte transport in the colon enables the development of new strategies for the treatment of CF and secretory diarrhea and will lead to a better understanding of the pathophysiological events during inflammatory bowel disease and development of colonic carcinoma.
Journal ArticleDOI
Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation : a double-blind, randomised, phase 3 trial
Harry G.M. Heijerman,Edward F. McKone,Damian G. Downey,Eva Van Braeckel,Steven M. Rowe,Elizabeth Tullis,Marcus A. Mall,John Welter,Bonnie W. Ramsey,Charlotte M. McKee,Gautham Marigowda,Samuel M. Moskowitz,David Waltz,Patrick R Sosnay,Christopher Simard,Neil Ahluwalia,Fengjuan Xuan,Yaohua Zhang,Jennifer L. Taylor-Cousar,Karen McCoy +19 more
TL;DR: Elexacaftor plus tezacaftorplus ivacaftors provided clinically robust benefit compared with tezacftor plus ivACaftor alone, with a favourable safety profile, and shows the potential to lead to transformative improvements in the lives of people with cystic fibrosis who are homozygous for the F508del mutation.